Immunome, Inc. · NASDAQ:IMNM
Immunome — Merger or Acquisition (June 2023)
27 slides from Immunome's merger presentation, Jun 29, 2023
Slide 1: Morphimmune and Immunome Combined Corporate Presentation
CONFIDENTIAL - DO NOT DISTRIBUTE Morphimmune and Immunome Combined Corporate Presentation June 2023
Slide 2: Disclaimer and Forward-Looking Statements
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of managemen
Slide 3: Combining Morphimmune and Immunome as the First Step to Establishing a Preeminent Oncology Company
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 3 Combining Morphimmune and Immunome as the First Step to Establishing a Preeminent Oncology Company Morphimmune • Led by Dr. Clay Siegall, Seagen founder and long-time Chairman & CEO • Strong scientific basis from founder Dr.
Slide 4: Management Team with a Demonstrated Track Record of Success
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 4 Immunome Team Management Team with a Demonstrated Track Record of Success Matthew Robinson, Ph.D. CHIEF TECHNOLOGY OFFICER Morphimmune Team Purnanand Sarma, Ph.D. PRESIDENT & CHIEF EXECUTIVE OFFICER Jack Higgins, Ph.D. CHIEF
Slide 5: Combined Company Pipeline Overview
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 5 Combined Company Pipeline Overview Discovery Lead Optimization Development Candidate IND-Enabling Anticipated IND Filing Anti-IL-38 (IMM20320) Solid Tumors 1Q2024 FA-TLR7a (Mi-1001) Solid Tumors 4Q2024 177Lu-FAP (Morphimmune)
Slide 6: Morphimmune and Immunome Merger Summary
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 6 Morphimmune and Immunome Merger Summary • Morphimmune and Immunome (NASD:IMNM) to merge with announcement planned in late June 2023 • $100 million PIPE expected to be announced at same time as merger agreement signing • Will
Slide 7: Combining Targeted Effector Technology with Antibody-Target Discovery Platform
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 7 Target Discovery Targeting Moieties Linkers Effectors Combining Targeted Effector Technology with Antibody-Target Discovery Platform Brings Synergistic Value • Screening strategy identifies antibodies to known and unknown ant
Slide 8: Programs: Anti-IL-38 (IMM20320)
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 8 Programs: Anti-IL-38 (IMM20320)
Slide 9: IL-38 Is an Immunosuppressive Cytokine with I/O Potential
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 9 IL-38 Is an Immunosuppressive Cytokine with I/O Potential IL-38 Function: Inhibits pro-inflammatory IL-36/IL-36R pathway1 1. Iznardo 2021 doi: 10.3390/ijms22094344 IL-1R!1 and IL1RAPL1 are also IL-38 cognate receptors 2. Han
Slide 10: Reduced Immune Cell Infiltration in IL-38 High Tumors
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 10 Reduced Immune Cell Infiltration in IL-38 High Tumors Poor Overall Survival in IL-38 High Lung Cancer Poor Survival for Cancer Patients with Tumors Expressing High IL-38 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 SKCM CESC LUAD ESCA LUS
Slide 11: IMM20320: Platform-Derived, Potential First-in-Class Anti-IL-38 mAb
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 11 IMM20320: Platform-Derived, Potential First-in-Class Anti-IL-38 mAb Inhibiting IL-38-mediated immunosuppression in cancer Selectively binds IL-38 in array of 20,000 human proteins Human Protein Binding Array IL-38 Binding In
Slide 12: Programs: FA-TLR7a (Mi-1001)
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 12 Programs: FA-TLR7a (Mi-1001)
Slide 13: Targeting FRβ restricts the scope of TLR7 activation, reducing toxicity
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 13 Targeting FRβ restricts the scope of TLR7 activation, reducing toxicity1 FRβ is expressed in the TME of multiple solid cancers • TLR7 is a pattern recognition receptor expressed in the endosome of many immune cells • Binding
Slide 14: Mi-1001 is Novel Folate Receptor-Targeted TLR7a
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 14 Mi-1001 is Novel Folate Receptor-Targeted TLR7a Expected to Avoid Limitations of TLR7/8a Antibody Conjugates Mi-1001 Expected Design Benefits: • Folate ligand6 delivers TLR7a directly to FRβ-expressing immune cells in tumor
Slide 15: Development Status: Mi-1001 repolarizes human M2 macrophages to M1 phenotype
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 15 Development Status: Mi-1001 repolarizes human M2 macrophages to M1 phenotype Human M2 Macrophage Assay Cytokine Levels in Healthy Mice Mi-1001 doesn’t cause cytokine release in tumor-free mice due to lack of cells coexpressi
Slide 16: Programs: 177Lu-FAP
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 16 Programs: 177Lu-FAP
Slide 17: FAP Is a Promising RLT Target with Pan-Cancer Potential
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 17 FAP Is a Promising RLT Target with Pan-Cancer Potential • Fibroblast Activation Protein (FAP) is a cell surface protease with low expression in normal tissue • FAP is overexpressed on cancer associated fibroblasts (CAFs), th
Slide 18: 177Lu-FAP Candidates are Rationally Designed Products Using Proprietary Targeted Effector Platform
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 18 177Lu-FAP Candidates are Rationally Designed Products Using Proprietary Targeted Effector Platform 1. Morphimmune analysis of clinical dosimetry data for FAPi-46, FAP2286, Pluvicto, and Lutathera Shortcomings of Current Clin
Slide 19: Development Status: Developing 177Lu-FAP Candidates with Best-in-Class Potential
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 19 Development Status: Developing 177Lu-FAP Candidates with Best-in-Class Potential In vivo data suggests albumin binder confers enhanced PK profile and biodistribution Note: Left panel: unpublished preclinical biodistribution
Slide 20: Immunome Discovery Platform
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 20 Immunome Discovery Platform
Slide 21: Antibody Discovery Engine
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 21 Antibody Discovery Engine 01 02 03 04 Patient immune systems recognize numerous disease-associated antigens, leading to the formation of memory B-cells Memory B-cells are isolated, expanded, and immortalized using proprietar
Slide 22: Differentiated Approach Interrogates Memory B-Cells to Identify Both Validated and Novel Oncology Targets
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 22 Differentiated Approach Interrogates Memory B-Cells to Identify Both Validated and Novel Oncology Targets Memory B-Cell Hybridoma Approach Increases Breadth of Screening • Memory B-cell response generated across course of di
Slide 23: High Throughput Platform Allows For Rapid Target Identification Across Multiple Cancer Types
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 23 High Throughput Platform Allows For Rapid Target Identification Across Multiple Cancer Types Modular Design Provides Opportunity to Expand Screening Capacity with Additional Investment Diverse Cancer Landscape Catalog at Ind
Slide 24: Strategic Discovery Collaboration with AbbVie
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 24 Strategic Discovery Collaboration with AbbVie Key Financial Terms • AbbVie option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from three specified tumor types • $30M upfront payment • Eligib
Slide 25: Near-Term Potential Inflection Points
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 25 Near-Term Potential Inflection Points 2023 2024 2025 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Anti-IL-38 (IMM20320) FA-TLR7a (Mi-1001) 177Lu-FAP Pipeline Expansion Business Development Merger & PIPE Organic pipeline expansion driven by
Slide 26: Prosecuting a Multi-Layered IP Strategy
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 26 Prosecuting a Multi-Layered IP Strategy COMPOSITION OF MATTER • Over 100 patents and patent applications across more than 20 families as of June 2023 • Covers Morphimmune’s targeting proprietary ligands and effectors, and le
Slide 27: Building the Foundation for a Premier Targeted Oncology Company
CONFIDENTIAL - DO NOT DISTRIBUTE M O R P H I M M U N E + I M M U N O M E 27 Building the Foundation for a Premier Targeted Oncology Company • Experienced management team led by CEO Clay Siegall, Seagen co-founder and long-time chairman & CEO, with headquarters in Seattle • Immunome’s antibody expert